Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer

  • Colomer, Carlota
  • Margalef, Pol
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Vert, Anna
  • Pecharroman, Irene
  • Solé Font, Laura|||0000-0002-3195-0565
  • Gonzàlez-Farré, Mònica|||0000-0002-0653-0980
  • Alonso, Josune|||0000-0001-6783-5166
  • Montagut, Clara
  • Martinez-Iniesta, Maria
  • Bertran, Joan
  • Borràs, Eva|||0000-0002-3859-9907
  • Iglesias, Mar|||0000-0002-2274-4671
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Boulton, Simon J.
  • Espinosa, Lluis|||0000-0002-2897-4099
Phosphorylated IKKα(p45) is a nuclear active form of the IKKα kinase that is induced by the MAP kinases BRAF and TAK1 and promotes tumor growth independent of canonical NF-κB signaling. Insights into the sources of IKKα(p45) activation and its downstream substrates in the nucleus remain to be defined. Here, we discover that IKKα(p45) is rapidly activated by DNA damage independent of ATM-ATR, but dependent on BRAF-TAK1-p38-MAPK, and is required for robust ATM activation and efficient DNA repair. Abolishing BRAF or IKKα activity attenuates ATM, Chk1, MDC1, Kap1, and 53BP1 phosphorylation, compromises 53BP1 and RIF1 co-recruitment to sites of DNA lesions, and inhibits 53BP1-dependent fusion of dysfunctional telomeres. Furthermore, IKKα or BRAF inhibition synergistically enhances the therapeutic potential of 5-FU and irinotecan to eradicate chemotherapy-resistant metastatic human tumors in vivo. Our results implicate BRAF and IKKα kinases in the DDR and reveal a combination strategy for cancer treatment. Colomer et al. discover that IKKα kinase contributes to the chemo- and radio-resistance of cancer cells by facilitating ATM activation and DNA repair. BRAF inhibitors prevent damage-induced IKKα activation, leading to the attenuation of ATM signaling and DNA repair. IKKα depletion or BRAF inhibitors combined with 5-FU and irinotecan synergistically enhance the killing of patient-derived xenograft tumors.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma

  • Gallardo, Fernando|||0000-0002-8996-3828
  • Bertran, Joan
  • López-Arribillaga, Erika|||0000-0002-9451-6635
  • González, Jéssica
  • Menéndez, Silvia
  • Sánchez, Ignacio
  • Colomo, Luis|||0000-0001-5236-5085
  • Iglesias, Mar|||0000-0002-2274-4671
  • Garrido, Marta
  • Santamaría-Babí, Luis Francisco
  • Torres, Ferran|||0000-0002-7355-7913
  • Pujol Vallverdú, Ramón M.|||0000-0002-5622-6055
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Espinosa, Lluis|||0000-0002-2897-4099
Cutaneous T-cell lymphomas (CTCLs) represent different subtypes of lymphoproliferative disorders with no curative therapies for the advanced forms of the disease (namely mycosis fungoides and the leukemic variant, Sézary syndrome). Molecular events leading to CTCL progression are heterogeneous, however recent DNA and RNA sequencing studies highlighted the importance of NF-κB and β-catenin pathways. We here show that the kinase TAK1, known as essential in B-cell lymphoma, is constitutively activated in CTCL cells, but tempered by the MYPT1/PP1 phosphatase complex. Blocking PP1 activity, both pharmacologically and genetically, resulted in TAK1 hyperphosphorylation at residues T344, S389, T444, and T511, which have functional impact on canonical NF-κB signaling. Inhibition of TAK1 precluded NF-κB and β-catenin signaling and induced apoptosis of CTCL cell lines and primary Sézary syndrome cells both in vitro and in vivo. Detection of phosphorylated TAK1 at T444 and T344 is associated with the presence of lymphoma in a set of 60 primary human samples correlating with NF-κB and β-catenin activation. These results identified TAK1 as a potential biomarker and therapeutic target for CTCL therapy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cells

  • López-Arribillaga, Erika|||0000-0002-9451-6635
  • Rodilla, Verónica|||0000-0003-0512-4179
  • Colomer, Carlota
  • Vert, Anna
  • Shelton, Amy
  • Cheng, Jason H.
  • Yan, Bing
  • Gonzalez-Perez, Abel|||0000-0002-8582-4660
  • Junttila, Melissa R.
  • Iglesias, Mar|||0000-0002-2274-4671
  • Torres, Ferran|||0000-0002-7355-7913
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Siebel, Christian W.
  • Espinosa, Lluis|||0000-0002-2897-4099
Delta ligands regulate Notch signaling in normal intestinal stem cells, while Jagged1 activates Notch in intestinal adenomas carrying active β-catenin. We used the Apc Min/+ mouse model, tumor spheroid cultures, and patient-derived orthoxenografts to address this divergent ligand-dependent Notch function and its implication in disease. We found that intestinal-specific Jag1 deletion or antibody targeting Jag1 prevents tumor initiation in mice. Addiction to Jag1 is concomitant with the absence of Manic Fringe (MFNG) in adenoma cells, and its ectopic expression reverts Jag1 dependence. In 239 human colorectal cancer patient samples, MFNG imposes a negative correlation between Jag1 and Notch, being high Jag1 in the absence of MFNG predictive of poor prognosis. Jag1 antibody treatment reduces patient-derived tumor orthoxenograft growth without affecting normal intestinal mucosa. Our data provide an explanation to Jag1 dependence in cancer, and reveal that Jag1-Notch1 interference provides therapeutic benefit in a subset of colorectal cancer and FAP syndrome patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis

  • Solé Font, Laura|||0000-0002-3195-0565
  • Lobo-Jarne, Teresa|||0000-0002-1632-438X
  • Álvarez-Villanueva, Daniel
  • Alonso-Marañón, Josune
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Guix, Marta|||0000-0002-2143-0697
  • Sangrador, Irene
  • Rozalén, Catalina
  • Vert, Anna
  • Barbachano, Antonio|||0000-0002-1248-5143
  • Lop Gros, Joan|||0000-0002-9442-5688
  • Salido, Marta|||0000-0001-9988-5977
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • García-Romero, Raquel
  • Garrido, Marta
  • González Miranda, Jessica|||0000-0001-7732-1564
  • Martínez-Iniesta, María
  • López-Arribillaga, Erika|||0000-0002-9451-6635
  • Salazar, Ramón
  • Torres, Ferran|||0000-0002-7355-7913
  • Iglesias, Mar|||0000-0002-2274-4671
  • Celià-Terrassa, Toni|||0000-0002-0615-8744
  • Muñoz, Alberto|||0000-0003-3890-4251
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Espinosa, Lluis|||0000-0002-2897-4099
Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that remain ineffective in a proportion of patients. Whether and how non-curative DNA damage-based treatment affects tumor cell behavior and patient outcome is primarily unstudied. Using CRC patient-derived organoids (PDO)s, we show that sublethal doses of chemotherapy (CT) does not select previously resistant tumor populations but induces a quiescent state specifically to TP53 wildtype (WT) cancer cells, which is linked to the acquisition of a YAP1-dependent fetal phenotype. Cells displaying this phenotype exhibit high tumor-initiating and metastatic activity. Nuclear YAP1 and fetal traits are present in a proportion of tumors at diagnosis and predict poor prognosis in patients carrying TP53 WT CRC tumors. We provide data indicating the higher efficacy of CT together with YAP1 inhibitors for eradication of therapy resistant TP53 WT cancer cells. Together these results identify fetal conversion as a useful biomarker for patient prognosis and therapy prescription.